Skip to main content
OpenTrials
Completed

NCT Number: NCT06167395

Study to Analyze the Aerobic Performance Efficacy of Chronic Intake With a β-alanine Supplement in Recreational Cyclists

Randomized, controlled, double-blind, double-blind clinical trial, with three parallel arms depending on the product consumed (experimental product dose 1 and dose 2 and placebo product) and single-center, to measure the efficacy of a sustained release beta alanine on the aerobic performance efficacy in recreational cyclist

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Beta Alanine Supplementation

Age range

18 year–60 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Catholic University of Murcia

Murcia, 30107, Spain

About this study

Subjects meeting the selection criteria will be randomly assigned to each of the study groups (investigational product dose 1 or dose 2, or placebo, depending on the group to which they have been assigned).

The product to be consumed is beta alanine. Participants will consume the product for 30 days. They will have to take 4 intakes every three hours, being the first intake two hours after waking up.

The study subjects will have to make 2 visits to the laboratory. At the first and last visit, their aerobic performance will be evaluated by an incremental test to exhaustion with gas analysis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male cyclists with more than two years of cycling experience.
  • Perform tests without fatigue.
  • Road bike training at least twice a week.

Exclusion criteria

  • Participants with chronic illness.
  • Have a long-term injury that prevents you from training in the previous month.
  • Inability to understand informed consent.
  • Have consumed beta alanine in the three years prior to the start of the study.
  • Consumption of other supplements that may alter performance.

Treatment and study plan

Beta Alanine high dose

Dietary Supplement

Subjects should consume 4 intakes of 5 g of beta alanine every 3 hours each day.

Beta Alanine low dose

Dietary Supplement

Subjects should consume 4 intakes of 2,5 g of beta alanine every 3 hours each day.

Control product

Dietary Supplement

Subjects should consume 4 intakes of 2,5 g of wheat semolina every 3 hours each day.

Primary outcomes

  1. Power

    Time frame: Change in performance after 30 days of product consumption

    Measured using a cyclus 2 roller.

  2. Distance

    Time frame: Change in performance after 30 days of product consumption

    Measured using a cyclus 2 roller.

Secondary outcomes

  1. Anaerobic treshold

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

    Through a stress test with gas analysis

  2. Maximum oxygen consumption

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

    Through a stress test with gas analysis

  3. Aerobic threshold

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

    Through a stress test with gas analysis

  4. Microcapillary blood

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

    This test provides biochemical variables (ABL90FLEX) with 70 ml of capillary blood.

  5. Lactate

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

    Lactate levels will be measured using the Lactate Pro 2

  6. Heart Rate

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

    The heart rate will be evaluated by means of a heart rate strap.

  7. Fatigue

    Time frame: It will be measured twice, once at baseline or at the end of the study after 30 days.

    Rate of perceived exertion

Sponsors and collaborators

Lead sponsor

Universidad Católica San Antonio de Murcia

Other

Registry information

Official study title

Randomized Clinical Trial to Analyze the Efficacy of Chronic Intake of Different Doses of a β-alanine Supplement on Aerobic Performance in Recreational Long-Distance Road Cyclists

Acronym: B-AC3

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Dec 12, 2023
Registry last updated
May 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.